Resources from the same session
93MO - Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
Presenter: Nadia Harbeck
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
94MO - The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy - DATA trial analysis
Presenter: Senna Lammers
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
260MO - Long term patient reported outcomes in premenopausal women with the hormone receptor positive breast cancer from ABCSG 22 Registry
Presenter: Vesna Bjelic-Radisic
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Mini Oral session 1
Resources:
Webcast
190MO - Association of 18-Gene Expression Profile (GEP) With Clinical Outcomes in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated With Pembrolizumab (Pembro) or Chemotherapy (Chemo) in KEYNOTE-119
Presenter: Peter Schmid
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
191MO - KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs
Presenter: Hope Rugo
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
1MO - Tumor immune microenvironment in ER-negative vs. ER-low, HER2-neg breast cancer
Presenter: Davide Massa
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 190MO, 191MO, 1MO and 2MO
Presenter: Marleen Kok
Session: Mini Oral session 1
Resources:
Slides
Webcast
2MO - Expression levels of immune checkpoint markers (IC) in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)
Presenter: Anirudh Pabba
Session: Mini Oral session 1
Resources:
Abstract
Q&A and discussion
Presenter: To be Announced
Session: Mini Oral session 1
Resources:
Webcast